You are about to announce a milestone. A trial readout, a regulatory submission, a new indication, a partnership. Your marketing team wants the release to sound like a win. Your medical and regulatory reviewers want it to survive scrutiny. And somewhere between those two pressures is a document that has to be both quotable and defensible, because a pharma press release is the one PR asset that a federal agency might read line by line.
This is what makes pharmaceutical communications harder than almost any other category of PR. A consumer brand that overstates a claim gets an eye-roll. A drug company that overstates a claim gets a letter from the FDA, a correction obligation, and a story that is now about the violation instead of the science. The good news is that the constraints are knowable, and a release written inside them can still be sharp, newsworthy, and worth a reporter’s time. Here is the playbook.
What makes pharma different from every other press release
Most press releases answer to no one but the editor’s interest. A pharma press release answers to the editor, to the FDA’s expectations around promotional communication, and, for public companies, to securities regulators who treat material trial results as disclosable information. Three audiences, three standards, one document.
The FDA’s core expectation is that promotional communication about a prescription drug is truthful, not misleading, and balanced. “Balanced” is the word that trips people. It means a release touting a benefit cannot stay silent on the relevant risks. A release that reads like pure good news, with no safety information anywhere, is the release most likely to draw attention. The agency has issued warning and untitled letters for years over promotional pieces that overstated efficacy, minimized risk, or implied a use the label does not support.
The second trap is the off-label line. A drug is approved for specific indications. A release that hints the drug helps with a condition outside the approved label, even through a hopeful quote or a suggestive headline, has crossed into off-label promotion. Reporters know this, regulators watch for it, and it is the single fastest way to turn an announcement into a problem.
A third difference is timing pressure. Public pharmaceutical companies sit under securities-disclosure rules, which means a material trial result cannot simply wait for the perfect news cycle. The release has to go out promptly, accurately, and in a form that satisfies both the FDA’s promotional expectations and the SEC’s disclosure expectations at once. That dual deadline is why pharma communications cannot be improvised. The compliant version of the release has to exist before the news is ready to break, because there is no time to build it from scratch once the clock starts.
Separate the announcement from the claim
The most useful habit in pharma writing is to draw a hard line between what happened and what it means. What happened is a fact: the trial enrolled this many patients, the submission was filed on this date, the endpoint was met. What it means is a claim: the drug works, patients will benefit, this changes treatment.
Facts are safe. Claims are where the risk lives. So write the release as a spine of facts, and let the claims appear only as attributed quotes from named people who are entitled to make them. A principal investigator can offer a measured interpretation of a result. A chief medical officer can speak to a development strategy. The release body itself stays factual, and the interpretation sits inside quotation marks, attributed to a human who owns it.
This structure also makes the release better journalism. Reporters distrust a corporate document that editorializes. They trust a document that lays out the facts cleanly and lets named sources interpret. The compliant structure and the credible structure are the same structure.
It also settles a political problem inside the company. Marketing wants the release to sound like a win, regulatory wants it to survive scrutiny, and the fact-spine-plus-attributed-claim structure gives both sides what they need. Marketing gets strong, quotable interpretation in the quotes. Regulatory gets a release body that makes only verifiable factual statements. The argument that usually plays out in tracked changes for two weeks gets resolved by the structure itself, because everyone can see which sentences are facts and which are claims, and the claims sit in a place where a named person owns them.
Build a claims ledger before you write
Before drafting, build what is worth calling a claims ledger. It is a simple two-column document. In the left column, list every claim the release will make or imply, including the soft ones buried in adjectives and quotes. In the right column, write the specific evidence that supports each claim and where that evidence is approved to appear.
A claim like “well tolerated” goes in the left column. The right column has to name the data: the adverse-event rates, the trial they came from, whether the label or the published results support that exact phrasing. If the right column is empty or vague, the claim does not go in the release. No exceptions.
The claims ledger does three things. It forces marketing and regulatory to argue on paper before the draft exists, which is faster than arguing in tracked changes later. It gives your reviewers a document they can approve clause by clause. And it becomes your defense file: if anyone ever questions the release, you can show exactly what supported every word. A pharma press release built from a completed ledger almost never surprises its own legal team, and that is the entire point.
The ledger has one more use that pays off later. Reporters, and occasionally regulators, ask follow-up questions weeks or months after a release goes out. A company without a ledger has to reconstruct, from memory and old drafts, what supported a given phrase. A company with a completed ledger pulls one document and answers in minutes. In a category where a single questioned claim can become a correction obligation, the ability to show your work, fast and completely, is worth far more than the hour the ledger took to build.
Why do reporters distrust pharma releases?
Health reporters have been burned. They have written up a trial result that the company framed as a breakthrough, only to learn the endpoint was a surrogate marker, the comparison arm was weak, or the effect size was small enough that a clinician would shrug. So they read pharma releases defensively, hunting for what the wording is hiding.
You earn their trust by handing over what they would otherwise have to dig for. State the endpoint plainly, and say whether it was primary or secondary. Give the effect size in absolute terms, not just a relative percentage that sounds dramatic and means little without the baseline. Name the comparator. Note the trial size and phase. Include the limitations a careful reporter would raise anyway.
This feels like undercutting your own announcement. It does the opposite. A release that pre-empts the skeptical questions reads as confident and credible, and confident and credible is what gets covered. A release that buries the limitations reads as evasive, and the reporter either ignores it or writes the story about what you hid.
There is a specific tell reporters watch for: the relative-risk number with no absolute number beside it. A release that says a drug “reduced the risk of an event by 50 percent” sounds dramatic and may be technically accurate, but if the event rate moved from 2 percent to 1 percent, the absolute benefit is one percentage point. Health reporters know this pattern well, and a release that uses the relative number alone reads as either naive or evasive. Give both numbers. The release that volunteers the absolute figure looks honest, and honest is what survives the fact-check and earns the next call.
What a compliant release still does well
None of this means the release has to be dull. Within the constraints, a pharma press release can still lead with genuine news, still carry a strong quote, still give a reporter a reason to call. The constraints govern accuracy and balance. They do not require boredom.
A strong compliant release opens with the most newsworthy verifiable fact, not a marketing windup. It quotes a credible named source who interprets without overreaching. It states the data honestly, including the parts that are not flattering. It includes the required safety and indication information without burying the announcement. And it gives reporters the contacts and backup, the trial registry number, the investigator availability, the published-data link, that let them verify fast.
Consider how the strongest biotech communicators handle a positive Phase 3 readout. They do not say the drug “works wonders.” They say the trial met its primary endpoint, give the absolute numbers, quote the lead investigator on what the result suggests for a specific patient population, and include the safety profile in the same breath. The announcement still lands as a win. It just lands as a win that nobody can take back.
The same discipline applies to the headline, which is the part of a pharma release most likely to overreach. A headline has to compress, and compression tempts exaggeration. “Breakthrough drug” and “game-changing results” are headline instincts that a regulatory reviewer will strike, and should. The headline can still be strong: it can name the milestone, the endpoint met, the indication, the trial phase. It just has to be as accurate as the body. A release whose body is careful and whose headline is not has not solved the problem, because the headline is the line that travels farthest and gets quoted most.
One more practice separates the strongest pharma communicators: the embargo. Major trial results are often shared with selected health reporters in advance, under an agreement not to publish until a set time, usually tied to a peer-reviewed journal publication or a conference presentation. A well-run embargo gives careful reporters the hours they need to read the data properly, call an independent expert for a second opinion, and write an accurate piece rather than a rushed one. Rushed pharma coverage is where errors and overstatements creep in, and an error in a story about your drug is a problem even when you did not write the story. The embargo is a tool for accuracy as much as timing. It gives the company a window to brief reporters on the trial’s design and limitations, so the resulting coverage reflects the science rather than a fast skim of a headline. Used well, the embargo turns a complex result into careful journalism. Used badly, broken early or offered to too many outlets at once, it collapses into the same scramble it was meant to prevent. Treat it as a structured handoff of complex information, not a publicity lever.
Write every pharma press release so that a year from now, with the release in front of you and a regulator across the table, there is not one word you would change.